[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 2336 Introduced in Senate (IS)]

<DOC>






119th CONGRESS
  1st Session
                                S. 2336

  To ensure references to opioid overdose reversal agents in certain 
 grant programs of the Department of Health and Human Services are not 
                          limited to naloxone.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             July 17, 2025

Mr. Cornyn (for himself and Ms. Hassan) introduced the following bill; 
     which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
  To ensure references to opioid overdose reversal agents in certain 
 grant programs of the Department of Health and Human Services are not 
                          limited to naloxone.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Halting the Epidemic of Addiction 
and Loss Act of 2025''.

SEC. 2. REFERENCES TO OPIOID OVERDOSE REVERSAL AGENTS IN HHS GRANT 
              PROGRAMS.

    (a) In General.--The Secretary of Health and Human Services shall 
ensure that, as appropriate, whenever the Department of Health and 
Human Services issues a regulation or guidance for any grant program 
addressing opioid misuse and use disorders, any reference to an opioid 
overdose reversal drug (such as a reference to naloxone) is inclusive 
of any opioid overdose reversal drug that has been approved under 
section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) 
for emergency treatment of a known or suspected opioid overdose.
    (b) Existing References.--
            (1) Update.--Not later than one year after the date of 
        enactment of this Act, the Secretary of Health and Human 
        Services shall update all references described in paragraph (2) 
        to be inclusive of any opioid overdose reversal drug that has 
        been approved or otherwise authorized for use by the Food and 
        Drug Administration.
            (2) References.--A reference described in this paragraph is 
        any reference to an opioid overdose reversal drug (such as 
        naloxone) in any regulation or guidance of the Department of 
        Health and Human Services that--
                    (A) was issued before the date of enactment of this 
                Act; and
                    (B) is included in--
                            (i) the grant program for State and Tribal 
                        response to opioid use disorders under section 
                        1003 of the 21st Century Cures Act (42 U.S.C. 
                        290ee-3a) (commonly referred to as ``State 
                        Opioid Response Grants'' and ``Tribal Opioid 
                        Response Grants''); or
                            (ii) the grant program for priority 
                        substance use disorder prevention needs of 
                        regional and national significance under 
                        section 516 of the Public Health Service Act 
                        (42 U.S.C. 290bb-22).
                                 <all>